• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


237.8000 DKK 4.0000 1.71%

As of 11:03:47 ET on 09/19/2014.

Snapshot for Genmab A/S (GEN)

Open: 235.0000 Day's Range: 233.3000 - 237.8000 Volume: 146,903
Previous Close: 233.8000 52wk Range: 180.1000 - 260.0000 1-Yr Rtn: +17.72%

Stock Chart for GEN

No chart data available.
  • GEN:DC 237.8000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 89.7753
Estimated P/E(12/2014) 60.8014
Relative P/E vs. KFX 3.9052
Earnings Per Share (DKK) (ttm) 2.6344
Est. EPS (DKK) (12/2014) 3.8930
Est. PEG Ratio 1.3706
Market Cap (M DKK) 13,438.23
Shares Outstanding (M) 56.82
30 Day Average Volume 138,914
Price/Book (mrq) 7.7012
Price/Sale (ttm) 17.2844
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/05/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil